Total submissions: 8
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Athena Diagnostics | RCV000516907 | SCV000616141 | uncertain significance | not specified | 2017-02-10 | criteria provided, single submitter | clinical testing | |
| Ambry Genetics | RCV002341215 | SCV002639317 | uncertain significance | Cardiovascular phenotype | 2020-02-11 | criteria provided, single submitter | clinical testing | The p.I15780L variant (also known as c.47338A>C), located in coding exon 153 of the TTN gene, results from an A to C substitution at nucleotide position 47338. The isoleucine at codon 15780 is replaced by leucine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
| Revvity Omics, |
RCV001701028 | SCV003819153 | uncertain significance | not provided | 2020-12-22 | criteria provided, single submitter | clinical testing | |
| Breakthrough Genomics, |
RCV001701028 | SCV005188117 | uncertain significance | not provided | criteria provided, single submitter | not provided | ||
| Mayo Clinic Laboratories, |
RCV001701028 | SCV005413035 | uncertain significance | not provided | 2023-12-07 | criteria provided, single submitter | clinical testing | BP4 |
| Clinical Genetics, |
RCV001701028 | SCV001918276 | uncertain significance | not provided | no assertion criteria provided | clinical testing | ||
| Diagnostic Laboratory, |
RCV001701028 | SCV001962893 | uncertain significance | not provided | no assertion criteria provided | clinical testing | ||
| Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV001701028 | SCV001979693 | uncertain significance | not provided | no assertion criteria provided | clinical testing |